-
公开(公告)号：US20180207146A1
公开(公告)日：2018-07-26
申请号：US15327247
申请日：2015-07-20
Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.
Inventor： Byoung Ki AHN , Ki Seong KO , So Hyun PARK , Min Hyo KI , Jong Lae LIM
IPC: A61K31/473 , A61K31/542 , A61K9/08 , A61K31/5415 , A61K31/405 , A61K31/407 , A61K9/00 , A61K47/14 , A61K47/24 , A61K47/28 , A61K47/22
CPC classification number: A61K31/473 , A61K9/0019 , A61K9/0095 , A61K9/08 , A61K31/135 , A61K31/405 , A61K31/407 , A61K31/4402 , A61K31/5415 , A61K31/542 , A61K31/573 , A61K31/58 , A61K45/06 , A61K47/14 , A61K47/22 , A61K47/24 , A61K47/28 , A61K2300/00
Abstract: Disclosed is a composition comprising a 5α-reductase inhibitor. Forming a liquid crystal upon exposure to an aqueous fluid, the composition can release the 5α-reductase inhibitor at a constant rate over a long period of time. In addition, the composition can significantly alleviate irritations attributed to the topical administration of the 5α-reductase inhibitor, and thus the composition has improved safety.
-
72.发明申请
公开(公告)号：US20180200263A1
公开(公告)日：2018-07-19
申请号：US15742727
申请日：2016-07-06
Applicant: Pearl E. Grimes
Inventor： Pearl E. Grimes
IPC: A61K31/557 , A61K31/58 , A61K36/82 , A61K38/13 , A61K31/353 , A61K31/436 , A61K9/00 , A61P17/00
CPC classification number: A61K31/557 , A61K9/0014 , A61K31/353 , A61K31/436 , A61K31/5575 , A61K31/573 , A61K31/58 , A61K36/82 , A61K38/13 , A61K2300/00 , A61P17/00
Abstract: Disclosed herein is a topical treatment regimen including a prostaglandin F2α analog and a topical steroid for treating skin conditions, including skin pigmentation disorders associated with hypopigmentation such as vitiligo and nonfacial vitiligo. Examples of prostaglandin F2α analogs include bimatoprost, carboprost, dinoprost, fluprostenol, latanoprost, prostamide F2α, tafluprost, travoprost, and unoprostone, with bimatoprost being preferred. Examples of topical steroids include aclometasone, betamethasone, clobetasol, clobetasone, diflucortolone, fluocinolone, fluprednidene, flurandrenolide, fluticasone, halometasone, hydrocortisone, methylprednisolone, mometasone, prednicarbate, and triamcinolone, with mometasone being preferred. The topical treatment regimen includes one or more topical compositions, with the prostaglandin F2α analog and the topical steroid being contained either in separate topical compositions or in the same topical composition.
-
73.发明申请
公开(公告)号：US20180193360A1
公开(公告)日：2018-07-12
申请号：US15917106
申请日：2018-03-09
Applicant: Tyme, Inc.
Inventor： Steven Hoffman
IPC: A61K31/58 , A61K45/06 , A61K38/31 , A61K38/12 , A61K31/55 , A61K31/19 , A61K31/4166 , A61K31/407 , A61K31/37 , A61K31/198 , A61K31/436
CPC classification number: A61K31/58 , A61K31/19 , A61K31/198 , A61K31/20 , A61K31/37 , A61K31/407 , A61K31/4166 , A61K31/436 , A61K31/455 , A61K31/55 , A61K31/568 , A61K38/12 , A61K38/31 , A61K45/06 , A61K2300/00
Abstract: The present disclosure is directed to methods of treating cancer comprising administering dihydrotestosterone, a dihydrotestosterone derivative, a dihydrotestosterone promoter, or a combination thereof to a patient in need of treatment.
-
74.发明授权
公开(公告)号：US10016536B2
公开(公告)日：2018-07-10
申请号：US15386662
申请日：2016-12-21
Applicant: COOK MEDICAL TECHNOLOGIES LLC
Inventor： John Jackson , Lindsay Stuart Machan , Kevin Letchford
IPC: A61K31/16 , A61L31/16 , A61L31/08 , A61K31/337 , A61L29/08 , A61L29/16 , A61K31/436 , A61K31/58 , A61M25/10 , A61M25/09
CPC classification number: A61L31/16 , A61K31/337 , A61K31/353 , A61K31/436 , A61K31/58 , A61L27/34 , A61L27/44 , A61L27/54 , A61L29/08 , A61L29/085 , A61L29/16 , A61L31/08 , A61L31/10 , A61L2300/416 , A61L2300/426 , A61L2300/602 , A61L2300/606 , A61L2300/61 , A61L2420/06 , A61M25/09 , A61M25/10 , A61M2025/105 , H05K999/99
Abstract: Various aspects of the present invention provide compositions and implantable devices including a water-insoluble therapeutic agent solubilized in a matrix of a gallate-containing compound. Other aspects provide methods of manufacturing and using such compositions and devices.
-
公开(公告)号：US20180169019A1
公开(公告)日：2018-06-21
申请号：US15735421
申请日：2016-06-07
Inventor： Uwe MUENSTER , Eva-Maria BECKER-PELSTER , Martin ROSENBRUCH , Shirui MAO , Ni RUI , Zhenglin LIANG
IPC: A61K9/16 , A61K31/197 , A61K31/58 , A61K9/00
CPC classification number: A61K9/1694 , A61K9/0073 , A61K9/0075 , A61K9/1635 , A61K9/1647 , A61K31/197 , A61K31/58
Abstract: The invention relates to a single-emulsion based process using polyvinylpyrrolidone as a porogenic agent for the preparation of porous microparticles for inhalation formulations for pulmonary drug delivery as well as the microparticles and the pharmaceutical compositions produced hereof.
-
公开(公告)号：US20180153907A1
公开(公告)日：2018-06-07
申请号：US15889307
申请日：2018-02-06
Applicant: Boehringer Ingelheim Vetmedica GmbH
Inventor： Balazs ALBRECHT , Michael AVEN , Janine LAMAR , Ingo LANG
CPC classification number: A61K31/58 , A61K9/0073 , A61K9/0078 , A61K9/008
Abstract: Methods of treating airway diseases in equines include administering to an equine an effective amount of ciclesonide or a pharmaceutically acceptable salt thereof or a composition including ciclesonide or a pharmaceutically acceptable salt thereof.
-
77.发明申请
公开(公告)号：US20180141971A1
公开(公告)日：2018-05-24
申请号：US15639702
申请日：2017-06-30
Applicant: Sage Therapeutics, Inc.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert J. Robichaud , Francesco G. Salituro , Richard T. Beresis
IPC: C07J43/00 , C07J9/00 , C07J7/00 , C07J17/00 , C07J33/00 , C07J1/00 , C07J13/00 , C07J3/00 , C07J21/00 , C07J41/00
CPC classification number: A61K31/58 , A61K31/573 , C07J1/0059 , C07J1/007 , C07J1/0074 , C07J3/00 , C07J3/005 , C07J5/0015 , C07J7/00 , C07J7/002 , C07J7/007 , C07J7/008 , C07J7/0085 , C07J9/00 , C07J13/007 , C07J15/00 , C07J17/00 , C07J21/00 , C07J31/006 , C07J33/002 , C07J41/0066 , C07J43/003
Abstract: Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, and R4b are as defined herein, and A is a carbon bound substituted or unsubstituted 5- to 6-membered heteroaryl ring as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
-
78.发明申请
公开(公告)号：US20180140616A1
公开(公告)日：2018-05-24
申请号：US15876101
申请日：2018-01-19
Applicant: William Jow
Inventor： William Jow
IPC: A61K31/573 , A61K31/58 , A61K31/56 , A61K31/165 , A61K31/137 , A61K31/553 , A61K31/506 , A61K31/55 , A61K31/343 , A61K31/4458 , A61K31/439 , A61K31/38 , A61K31/335 , A61K31/381 , A61K31/15 , A61K31/42 , A61K31/53 , A61K31/5375 , A61K31/496 , A61K31/4525 , A61K31/435 , A61K31/19 , A61K47/44 , A61K47/10 , A61K47/12 , A61P29/00 , A61P1/00 , A61P31/04 , A61P31/12 , A61P31/00
CPC classification number: A61K31/573 , A61K9/0014 , A61K9/06 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/19 , A61K31/335 , A61K31/343 , A61K31/38 , A61K31/381 , A61K31/42 , A61K31/435 , A61K31/439 , A61K31/4458 , A61K31/4525 , A61K31/496 , A61K31/506 , A61K31/53 , A61K31/5375 , A61K31/55 , A61K31/553 , A61K31/56 , A61K31/58 , A61K47/10 , A61K47/12 , A61K47/44 , A61P1/00 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/12
Abstract: This invention relates to a novel method of treating various inflammation-related anorectal and genitourinary conditions using various related, novel formulations. The formulations comprise, at a minimum, a corticosteroid, an antidepressant agent(s) with anti-allergic and/or anti-itch properties and a cooling/soothing agent(s). Selection of specific ingredients depends on the nature of the target tissues, the etiologies of inflammation and the severity of symptoms. To maximize its efficacy, each of the formulations has a unique combination of several active ingredients, and each of these ingredients exerts its anti-inflammatory effect at various phases of the inflammatory cascade, resulting in a synergistic effect of pain relief and healing. To minimize the side effects, the current multi-active ingredient formulations allow each of these ingredients to exist at a lower concentration than the existing single-active ingredient formulations, thus minimizing the likelihood for side effects due to systemic absorption and toxicity. The formulations are highly versatile in that the composition of the ingredients can be varied and adjusted to treat a wide array of anorectal and genitourinary conditions.
-
公开(公告)号：US20180140614A1
公开(公告)日：2018-05-24
申请号：US15874521
申请日：2018-01-18
Applicant: Therapeutics Incorporated
Inventor： Robert T. Gauthier , James D. Hammer
IPC: A61K31/573 , A61K47/10 , A61K9/12 , A61K31/58 , B65D83/14 , A61K47/44 , B65B63/08 , A61K9/00 , A61K47/06 , A61K47/12 , B65B31/00
CPC classification number: A61K31/573 , A61K9/0014 , A61K9/122 , A61K31/58 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/44 , B65B31/003 , B65B63/08 , B65D83/752
Abstract: The present invention provides a method of manufacturing foamable, corticosteroid containing compositions as well as methods for treating various skin diseases.
-
公开(公告)号：US20180125864A1
公开(公告)日：2018-05-10
申请号：US15575537
申请日：2015-07-02
Applicant: INTELLIGENT SYNTHETIC BIOLOGY CENTER
Inventor： Chul Hee Choi , Eun Soo Kim , Kyung Sun Choi , Seung Wook Ryu , Jin Gang Hou
CPC classification number: A61K31/58 , A61K31/704 , A61P25/16 , C07J5/0015 , C07J9/00 , C07J17/005 , G01N33/502
Abstract: The present invention is directed to a method for screening a regulator of mitochondrial fission using a cell treated to a protopanaxadiol (PPD)-type ginsenoside compound, a composition therefor, and a kit comprising the composition. As the use of the method for screening the regulator of mitochondrial fission of the present invention enables effective discovery of a formulation capable of preventing, improving, or treating a mitochondria-related disease, the method will be widely used for the development of a therapeutic agent for the mitochondria-related disease.
